Marika J Suttorp

Medicine · Health Sciences

42h-index13.0kcitations365works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bone health and treatments(35), Bone health and osteoporosis research(24), Health Systems, Economic Evaluations, Quality of Life(23), Urinary Bladder and Prostate Research(20), Pelvic floor disorders treatments(19)

Publications365 total

Abstracts\' Service
The Indian Journal of Chest Diseases and Allied Sciences·2022Open Access
Symptom persistence in a community cohort of women with interstitial cystitis/bladder pain syndrome (IC/BPS): 3-, 6-, 9-, and 12-month follow-up from the RICE cohort
International Urogynecology Journal·2014· 13 citedOpen Access
Spinal manipulative therapy for low-back pain
Cochrane Database of Systematic Reviews·2013· 10 citedOpen Access
Table of Contents
Urology·2012Open Access
Temporal Ordering of Interstitial Cystitis/Bladder Pain Syndrome and Non-bladder Conditions
Urology·2012· 41 citedOpen Access
The Prevalence and Overlap of Interstitial Cystitis/Bladder Pain Syndrome and Chronic Prostatitis/Chronic Pelvic Pain Syndrome in Men: Results of the RAND Interstitial Cystitis Epidemiology Male Study
The Journal of Urology·2012· 293 citedOpen Access
Health-related quality of life in patients with interstitial cystitis/bladder pain syndrome and frequently associated comorbidities
Quality of Life Research·2012· 38 citedOpen Access
69 THE PREVALENCE OF INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME (IC/BPS) AND CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME (CP/CPPS) IN MEN; RESULTS OF THE RAND INTERSTITIAL CYSTITIS EPIDEMIOLOGY (RICE) MALE STUDY
The Journal of Urology·2012· 4 cited
818 THE IMPACT OF NON-UROLOGIC CONDITIONS ON QUALITY OF LIFE IN PATIENTS WITH INTERSTITIAL CYSTITIS
The Journal of Urology·2012
Two methods provide similar signals for the need to update systematic reviews
Journal of Clinical Epidemiology·2012· 42 citedOpen Access
Table 11, Pooled risk estimates of fracture for ibandronate, relative to lower dose, placebo, or no treatment, among postmenopausal women
2012
Table 40, Alfacalcidol plus prednisolone and alendronate versus alfacalcidol plus prednisolone
2012
Table 4, Pooled risk estimates of fracture risk associated with alendronate, relative to placebo or no treatment, among postmenopausal women*
2012
Table 54, Risks of adverse events for parathyroid hormone versus placebo
2012
Table 20, Pooled risk estimates of fracture for parathyroid hormone relative to placebo or no treatment*
2012
Table 44, Fractures with etidronate relative to calcitonin, by fracture type
2012
Figure 3, Total serious gastrointestinal adverse events in trials of alendronate versus placebo
2012
Table 10, Randomized controlled trials included in systematic review of effect of ibandronate on fracture relative to placebo or no treatment by fracture type
2012
Figure 17, Breast abnormalities (other than cancer) in trials of raloxifene versus placebo
2012
Table 8, Risk of fracture for risedronate, relative to placebo, by dose and fracture group
2012
page 1 of 19Next →

Frequent Co-authors

Paul G Shekelle(22), Margaret Maglione(17), Sally C. Morton(15), Sydne J Newberry(12), Walter Mojica(11), Lara Hilton(11), Sandra H. Berry(9), J. Quentin Clemens(9), Marc N. Elliott(7), Paul Shekelle(6), Melinda A. Maggard(5), Shannon Rhodes(5), Laura M. Bogart(5), Brett Ewing(4), Annie Zhou(4), Breanne Johnsen(4), Lara Jungvig(4), Susanne Hempel(4), Lisa R. Shugarman(3), Edward H. Livingston(3)